Business
Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting
SHANGHAI & CAMBRIDGE, Mass., March 26, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from preclinical studies of the Company’s internally discovered and developed next-generation, investigational oncology therapies, ZL-6201, an LRRC15 antibody-drug conjugate (ADC) for the treatment of sarcoma, and ZL-1222, a PD-1 targeted IL-12 immunocytokine for cancer immunotherapy, will be presented during poster sessions at the upcoming American Association for Cancer Research (A
About this update from Zai Lab Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":224,"url":"https://media.zenfs.com/en/business-wire.com/6dcac58fd9a0f7950f900514715284f8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pcO_lHOyaTs83kQfxYxlWA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ0ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/6dcac58fd9a0f7950f900514715284f8","width":480,"height":224}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Poster presentation will highlight the potential of ZL-6201 as an innovative antibody-drug conjugate (ADC) for the treatment of sarcoma and other leucine-rich repeat-containing protein 15 (LRRC15)-positive solid tumors","length":218,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":218,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Late-breaking poster presentation will summarize data from preclinical evaluation of ZL-1222, a promising next-generation interleukin-12 (IL-12) immunocytokine therapy for the treatment of various cancers","length":204,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":204,"olType":false},{"type":"text","content":"SHANGHAI & CAMBRIDGE, Mass., March 26, 2025--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from preclinical studies of the Company’s internally discovered and developed next-generation, investigational oncology therapies, ZL-6201, an LRRC15 antibody-drug conjugate (ADC) for the treatment of sarcoma, and ZL-1222, a PD-1 targeted IL-12 immunocytokine for cancer immunotherapy, will be presented during poster sessions at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025 taking place April 25-30, 2025 in Chicago, Illinois.","length":598,"tagName":"p"},{"type":"text","content":""Aligned with our strategy for our internally developed global oncology pipeline, ZL-6201 and ZL-1222 are promising investigational compounds with the potential to address multiple cancer types, including several that remain challenging to treat with current standard-of-care therapies," said Rafael G. Amado, M.D., President, Head of Global Research and Development at Zai Lab.","length":388,"tagName":"p"},{"type":"text","content":"LRRC15 i...